These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27142351)

  • 1. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.
    Ding G; Chen H
    Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcome of haploidentical hematopoietic stem cell transplantation for refractory/relapsed acute leukemia].
    Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Fu HX; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):917-21. PubMed ID: 23363748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
    Greiner J; Götz M; Bunjes D; Hofmann S; Wais V
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31878060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy analysis of unrelated donor hematopoietic stem cell transplantation for treatment of high risk acute myeloid leukemia].
    Ye F; Tang XW; Sun AN; Qiu HY; Jin ZM; Fu ZZ; Chen F; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):696-701. PubMed ID: 23815925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2017 Oct; 9(13):1115-1125. PubMed ID: 29032733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease.
    Curley C; Hill GR; McLean A; Kennedy GA
    Int J Lab Hematol; 2014 Apr; 36(2):197-204. PubMed ID: 24112249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
    Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
    Front Immunol; 2021; 12():695051. PubMed ID: 34413848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
    Liu J; Zhong JF; Zhang X; Zhang C
    J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
    Liu N; Ning HM; Hu LD; Jiang M; Xu C; Hu JW; Wang J; Li YH; Li BT; Lou X; Yang F; Chen JL; Su YF; Li M; Wang HY; Ren J; Feng YQ; Zhang B; Wang DH; Chen H
    Leuk Res; 2015 Dec; 39(12):1375-81. PubMed ID: 26530539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
    O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.